SLC5A2 and type 2 diabetes mellitus: Overall, these favorable cardiac effects may explain why SGLT2-Is may prevent HF in the experimental setting and reduce in T2DM patients the risk of mortality and admission to hospital for HF more than GLP-1 RAs, being the latter more effective in reduction of non-fatal stroke [194,203,204].